Lipid nanoparticles ? Metvan: reveling a novel way to deliver a vanadium compound to bone cancer cells

CACICEDO M.L.; RUIZ M.C.; SCIOLI-MONTOTO S.,; RUIZ M.E.; FERNÁNDEZ, MARIELA A.; ROSA M. TORRES SÁNCHEZ; BARAN E.J.; CASTRO G.R.; LEON I.E.

NEW JOURNAL OF CHEMISTRY

ROYAL SOC CHEMISTRY

Lugar: CAMBRIDGE; Año: 2019

1144-0546

Cancer is one of the main causes of mortality worldwide. Common therapy schemes arealways based on chemotherapy, radiotherapy and/or surgery. Among chemotherapeutics,vanadium compounds have recently emerged as non-platinum antitumor agents.In this sense, Metvan ([VIVO(Me2phen)2(SO4)]) was identified as one of the mostpromising vanadium anticancer complexes. In this work, Metvan compound wasencapsulated into well designed and developed nanostructured lipid carriers (NLCs) withthe aim of improving its biopharmaceutical profile by means of bioavailability,degradation, solubility and cell up-take. A quality by design approach was performed tofind the optimal nanoparticle formulation for Metvan delivery. Results exhibited that theideal formulation was obtained by using myristyl myristate as the lipid matrix andPluronic F128 as the stabilizing agent with a mean nanoparticle size of 230.8 ± 3.1 nmand a mean surface charge of -7.9 ± 0.8 mV. The formulation showed an encapsulationefficiency of approximately 80% with a drug sustained release for more than 60 h. Thekinetic release mechanism of Metvan from nanoparticles fitted Korsmeyer?Peppas model,indicating the Fickian diffusion of Metvan from the nanoparticles. On the other hand, theresults showed that the nanoparticles-Metvan system is more effective to decrease cellviability on human osteosarcoma cells (MG-63) than free drug, suggesting a possible different cell internalization mechanism and intracellular effect.